DMTs are major clinical research focus for Parkinson’s disease, analysis shows
Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...
Mena FN3d
Glaucoma Therapeutics Market Analysis By Size, Share, And Growth Market Value 8.02 Billion By 2031 At 3.2% CAGR
These efforts include developing new pharmacological agents, such as neuroprotective drugs and sustained-release formulations, to enhance patient compliance and therapeutic efficacy. This reflects a ...
Healthcare Asia on MSN4d
7MM Parkinson’s disease pipeline focuses on disease-modifying agents
There are a total of 93 products in Phase I-III development for PD treatment. The Parkinson’s disease (PD) therapeutic ...
The Financial Express4d
Parkinson’s disease clinical research in seven major markets focuses on disease-modifying agents
66% of these are prospective neuroprotective agents or DMTs. These investigational agents target the key mechanisms that have been implicated in the pathophysiology of PD, such as alpha-synuclein ...
The Pharma Letter5d
Growing emphasis on disease-modifying therapies in Parkinson’s
The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective ...